Role of Physiotherapist in enhancing functional aerobic capacity in pulmonary rehabilitation in Covid-19 Patients.

Not Applicable

Completed

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

• Registration Number: CTRI/2020/11/028811
• Lead Sponsor: Apollo Hospitals Educational and Research Foundation AHERF

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-01-30
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

1.Age -20-60

2.Haemoglobin > 9 mmHg

3.Covid positive patientâ??s mild, asymptomatic, moderate symptomatic with mild pneumonia.

4.Respiratory rate less than 30 breaths/min.

5.Spo2 more than 90%.

6.No amputations or prostheses in lower extremities

7.Able to ambulate and ability to complete all study protocol tests

8.Likelihood of good compliance to the protocol.

9.Approval by referring Physician.

Exclusion Criteria

1.Patient has immediate plans to transfer to outside hospital

2.Patient requires significant doses of vasopressors for hemodynamic stability (maintain mean arterial pressure > 60 mm Hg)

3.Patient is mechanically ventilated and requires Fio2â?¯ > 0.8 and/or positive end-expiratory pressure > 12 mm Hg, or has acutely worsening respiratory failure

4.Patient is maintained on neuromuscular paralytic agents

5.Patient has an acute neurologic event (e.g., cerebrovascular accident, subarachnoid haemorrhage, or intracranial haemorrhage) with reassessment for mobility every 24 hours

6.Patient is unresponsive to verbal stimuli

7.Patient has an unstable spine or extremity fracture

8.Patient has a grave prognosis and is transferring to comfort care

9.Patient has an open abdomen with a risk for dehiscence

10.Severe pneumonia and on oxygen therapy.

11.Breathing rate more than 30 breaths / min, spo2 less than 90.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.VO2max.2.Rate of perceived exertion 3.WHOQOL-BREF 4. NODIC-Musculoskeletal questionnaireTimepoint: 7 days

Secondary Outcome Measures

Name	Time	Method
1.Improved quality of life. <br/ ><br>2. Reduced length of stay. <br/ ><br>3. Reduced fatigue and exertion during activities. <br/ ><br>4.Improved Vital functions. <br/ ><br>5. Improved endurance. <br/ ><br>6.Improving immunity.Timepoint: 7 days